International Journal of Hematology

, 77:93

Thrombocytopenia Induced by Imatinib Mesylate (Glivec) in Patients with Chronic Myelogenous Leukemia: is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients?

  • Keisuke Miyazawa
  • Jiroh Nishimaki
  • Tomoko Katagiri
  • Goro Sashida
  • Nahoko Shoji
  • Ken Kawakubo
  • Akitaka Suzuki
  • Takashi Shimamoto
  • Akihiko Gotoh
  • Yuzuru Kuriyama
  • Yoshikazu Ito
  • Tetsuzo Tauchi
  • Yoshikazu Kawanishi
  • Yukihiko Kimura
  • Kazuma Ohyashiki
Letter to the Editor

DOI: 10.1007/BF02982610

Cite this article as:
Miyazawa, K., Nishimaki, J., Katagiri, T. et al. Int J Hematol (2003) 77: 93. doi:10.1007/BF02982610

Copyright information

© The Japanese Society of Hematology 2003

Authors and Affiliations

  • Keisuke Miyazawa
    • 1
  • Jiroh Nishimaki
    • 1
  • Tomoko Katagiri
    • 1
  • Goro Sashida
    • 1
  • Nahoko Shoji
    • 1
  • Ken Kawakubo
    • 1
  • Akitaka Suzuki
    • 1
  • Takashi Shimamoto
    • 1
  • Akihiko Gotoh
    • 1
  • Yuzuru Kuriyama
    • 1
  • Yoshikazu Ito
    • 1
  • Tetsuzo Tauchi
    • 1
  • Yoshikazu Kawanishi
    • 2
  • Yukihiko Kimura
    • 1
  • Kazuma Ohyashiki
    • 1
  1. 1.First Department of Internal MedicineTokyo Medical UniversityTokyoJapan
  2. 2.Health Care and Health Science InstituteTokyo Medical University HospitalTokyoJapan